BOSTON--(BUSINESS WIRE)--HepaLife Technologies, Inc. (OTCBB:HPLF) (FWB:HL1) (WKN:500625) today announced that results from new tests of the Company’s patented PICM-19 liver cells show the highest levels of important liver-specific metabolic activity key to mimicking human liver function, and further demonstrate the PICM-19’s ability to perform equivalent to freshly harvested adult porcine hepatocytes, traditionally regarded the best available liver cell source for bioartificial liver support. HepaLife’s PICM-19 liver cells also significantly outperform the world’s most widely used human liver cell line.
